FrancophonIA/ELRC3.0 huggingface dataset:
English: No pharmacokinetic data for zoledronic acid are available in patients with hypercalcaemia or in patients with hepatic insufficiency.
Estonian: Puuduvad andmed zoledroonhappe farmakokineetika kohta hüperkaltseemia või maksapuudulikkusega patsientidel.
English: Your doctor may advise you to take calcium and vitamin D supplements (e.g. tablets) for at least the first ten days after being given Zoledronic Acid Hospira.
Estonian: Arst soovitab teil kasutada kaltsiumi ja D-vitamiini preparaate (näiteks tablette) vähemalt esimese kümne päeva jooksul pärast Zoledronic Acid Hospira manustamist.
English: In paediatric patients with severe osteogenesis imperfecta, zoledronic acid seems to be associated with more pronounced risks for acute phase reaction, hypocalcaemia and unexplained tachycardia, in comparison to pamidronate, but this difference declined after subsequent infusions.
Estonian: Raskekujulise osteogenesis imperfecta'ga lastel tundub zoledroonhape olevat seotud enam väljendunud riskiga ägeda faasi reaktsiooni, hüpokaltseemia ja ebaselge põhjusega tahhükardia tekkeks võrreldes pamidronaadiga, aga see erinevus vähenes pärast järgmisi infusioone.
English: - In vitro: Inhibition of osteoblast proliferation, direct cytostatic and pro-apoptotic activity on tumour cells, synergistic cytostatic effect with other anti-cancer medicinal products, anti-adhesion/invasion activity.
Estonian: - In vitro: osteoblastide paljunemise inhibeerimine; otsene tsütostaatiline ja pro-apoptootiline toime tuumori rakkudesse; sünergistlik tsütostaatiline toime koos teiste vähivastaste ravimitega; antiadhesiivne/-invasiivne toime.
English: In Paget's disease, bone remodelling is too rapid and new bone is formed in a disordered fashion, which makes it weaker than normal.
Estonian: Pageti tõve korral toimub remodelleerumine liiga kiiresti, uus luukude moodustub ebakorrapäraselt ja see muudab luu normaalsest nõrgemaks.
English: In patients with mild to moderate renal impairment, reduced doses should be prepared as instructed below.
Estonian: Kerge kuni mõõduka neerukahjustusega patsientide puhul tuleb ette valmistada vähendatud annused, nagu allpool kirjeldatud:
English: The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone, but the precise molecular mechanism leading to the inhibition of osteoclastic activity is still unclear.
Estonian: Bisfosfonaatide selektiivse toime aluseks on tugev afiinsus mineraliseerunud luu maatriksi suhtes, kuid osteoklastilise aktiivsuse inhibeerimise täpne toimemehhanism on siiani ebaselge.
English: There was faster normalisation of corrected serum calcium at day 4 for 8 mg zoledronic acid and at day 7 for 4 mg and 8 mg zoledronic acid.
Estonian: Korrigeeritud seerumi kaltsiumisisaldus normaliseerus kiiremini, 4. päevaks 8 mg zoledroonhappe grupis ja 7. päevaks 4 mg ja 8 mg zoledroonhappe grupis.
English: Your doctor will advise you and decide how long you should be treated with Zoledronic Acid Hospira.
Estonian: Arst annab teile nõu ning otsustab, kui kaua te peaksite saama ravi Zoledronic Acid Hospira'ga.
English: The total body clearance is 5.04 ± 2.5 l/h, independent of dose, and unaffected by gender, age, race, and body weight.
Estonian: Kogukliirens on 5,04  2,5 l/t sõltumata annusest, soost, vanusest, rassist ja kehakaalust.
English: If a lower dose of Zoledronic Acid Hospira is required, first withdraw the appropriate volume as indicated below and then dilute it further with 100 ml of infusion solution.
Estonian: Kui vajalik on väiksem Zoledronic Acid Hospira annus, võtke vastavalt väiksem kogus kontsentraati nagu kirjeldatud allpool ja seejärel lahjendage see 100 ml infusioonilahusega.
English: How often Zoledronic Acid Hospira is given - If you are being treated for the prevention of bone complications due to bone metastases, you will be given one infusion of Zoledronic Acid Hospira every three to four weeks.
Estonian: Kui tihti Zoledronic Acid Hospira't manustatakse - Kui teid ravitakse luumetastaasidest põhjustatud luutüsistuste ennetamiseks, manustatakse teile üks Zoledronic Acid Hospira infusioon iga kolme kuni nelja nädala tagant.
English: An extension study was conducted in order to examine the long-term general and renal safety of once yearly or twice yearly zoledronic acid over the 12-month extension treatment period in children who had completed one year of treatment with either zoledronic acid or pamidronate in the core study.
Estonian: Viidi läbi jätku-uuring, et hinnata zoledroonhappe üks kord ja kaks korda aastas manustamise pikaajalist üldist ja renaalset ohutust 12kuulise jätkuravi perioodi jooksul lastel, kes olid põhiuuringu raames saanud ühe aasta vältel ravi zoledroonhappe või pamidronaadiga.
English: Zoledronic acid 8 mg (N=90)
Estonian: Zoledroonhape 8 mg (n=90)
English: No dose adjustment is necessary in patients with creatinine clearance 35 ml/min.
Estonian: Annuse kohandamine ei ole vajalik patsientidel, kelle kreatiniini kliirens on ≥ 35 ml/min.
English: The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks.
Estonian: Uuringu raviperiood kestis 12 kuud, millele eelnes 4…9-nädalane skriiningperiood, mille jooksul võtsid patsiendid vähemalt 2 nädalat D-vitamiini ja kaltsiumilisandit.
English: It belongs to a group of medicines called bisphosphonates and is used to treat Paget's disease of the bone in adults.
Estonian: Ravim kuulub bisfosfonaatide ravimigruppi ja seda kasutatakse Pageti luutõve raviks täiskasvanutel.
English: The infusion time must not be less than 15 minutes.
Estonian: Infusiooniaeg ei tohi olla lühem kui 15 minutit.
English: There is no evidence to suggest that any extra precautions are needed.
Estonian: Seniste tulemuste põhjal ei ole täiendavad ettevaatusabinõud vajalikud.
English: In a large clinical trial in 7,736 patients, osteonecrosis of the jaw has been reported in one patient treated with zoledronic acid and one patient treated with placebo.
Estonian: 7736 patsiendiga mahukas kliinilises uuringus teatati lõualuu osteonekroosist ühel zoledroonhappega ravitud patsiendil ja ühel platseeboga ravitud patsiendil.
English: The pain score for zoledronic acid was consistently below baseline and pain reduction was accompanied by a trend in reduced analgesics score.
Estonian: Valu skoor jäi zoledroonhappe grupis püsivalt alla algväärtuse ning valu vähenemisega kaasnes analgeesia skoori vähenemine.
English: The mechanism behind the increased incidence of atrial fibrillation is unknown.
Estonian: Kodade fibrillatsiooni esinemissageduse suurenemise mehhanism on teadmata.
English: Your doctor will inform you regarding the symptoms associated with hypocalcaemia.
Estonian: Arst selgitab teile hüpokaltseemia tekkimisel esinevaid sümptomeid.
English: Over the first 24 hours, 39 ± 16% of the administered dose is recovered in the urine, while the remainder is principally bound to bone tissue.
Estonian: Esimese 24 tunni jooksul eritub uriiniga 39  16% manustatud annusest, ülejäänud seondub luukoega.
English: Very common (may affect more than 1 in 10 people): − Low level of phosphate in the blood.
Estonian: Väga sage (võivad esineda enam kui ühel inimesel 10-st): - Madal fosfaaditase veres.
English: The SRE rate (events/person year) was 0.628 for zoledronic acid and 1.096 for placebo.
Estonian: LST kordaja (juhud isiku kohta aastas) oli zoledroonhappe grupis 0,628 ja platseebogrupis 1,096.
English: It is especially important for your doctor to know all the medicines you are taking, especially if you are taking any medicines known to be harmful to your kidneys (e.g. aminoglycosides) or diuretics (“waterpills”) that may cause dehydration.
Estonian: Teie arsti jaoks on oluline teada kõiki ravimeid, mida te võtate, iseäranis, kui te võtate mõnd teist ravimit, mis võib teadaolevalt olla kahjulik neerudele (nt aminoglükosiidid) või diureetikume (“vee väljaajamise rohud”), mis võivad põhjustada organismis vedelike puudust (dehüdratsiooni).
English: The mean time of ending the Extended Observation Period due to the need for Paget's re-treatment from the initial dose was longer for zoledronic acid (7.7 years) than for risedronate (5.1 years).
Estonian: Keskmine aeg Pageti tõve korduva ravi vajaduse tõttu jätku-uuringu lõpetamiseni alates esialgsest annusest oli zoledroonhappe korral pikem (7,7 aastat) kui risedroonhappe korral (5,1 aastat).
English: Bone biopsy results showed bone of normal quality with no evidence of impaired bone remodelling and no evidence of mineralisation defects.
Estonian: Luu biopsia tulemused näitasid luukoe normaalset kvaliteeti, kusjuures ei täheldatud häireid luu remodelleerumises ning mineralisatsiooni defekte.
English: Each pack contains one vial with concentrate.
Estonian: Igas pakendis on üks viaal kontsentraadiga.
English: The overall percentage of patients who experienced adverse reactions were 44.7%, 16.7% and 10.2% after the first, second and third infusion, respectively.
Estonian: Keskmine patsientide protsent, kellel esinesid kõrvaltoimed, oli peale esimest, teist ja kolmandat infusiooni vastavalt 44,7%, 16,7% ja 10,2%.
English: How much Zoledronic Acid Hospira is given - The usual single dose given is 4 mg. - If you have a kidney problem, your doctor will give you a lower dose depending on the severity of your kidney problem.
Estonian: Kui suur on teile manustatav Zoledronic Acid Hospira annus - Tavaline manustatav üksikannus on 4 mg. - Kui teil on mõni neeruhaigus, võib arst määrata väiksema annuse sõltuvalt teie neeruhaiguse raskusastmest.
English: The incidence of post-dose symptoms occurring within the first three days after administration of Zoledronic Acid Hospira can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic Acid Hospira administration.
Estonian: Esimese kolme päeva jooksul pärast Zoledronic Acid Hospira manustamist esinevaid manustamisjärgseid sümptomeid saab vähendada, kui manustada paratsetamooli või ibuprofeeni vahetult pärast Zoledronic Acid Hospira manustamist.
English: As with other bisphosphonates, the retention time of zoledronic acid in bones is very long.
Estonian: Sarnaselt teiste bisfosfonaatidega püsib zoledroonhape luudes väga pikka aega.
English: Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
Estonian: Täpne teave selle ravimi kohta on Euroopa Ravimiameti kodulehel: http://www.ema.europa.eu.
English: In patients with renal impairment, the systemic exposure to concomitant medicinal products that are primarily excreted via the kidney may increase.
Estonian: Neerukahjustusega patsientidel võib samaaegsel kasutamisel suureneda peamiselt renaalsel teel eritatavate ravimite süsteemne ekspositsioon.
English: Zoledronic acid is not highly bound to plasma proteins (approximately 43-55% bound) and binding is concentration independent.
Estonian: Zoledroonhape ei seondu kuigi suurel määral plasmavalkudega (seondub ligikaudu 43...55%) ja siduvus ei sõltu kontsentratsioonist.
English: - Pregnancy and breast-feeding (see section 4.6).
Estonian: - Rasedus ja imetamine (vt lõik 4.6).
English: Caution is indicated when zoledronic acid is used with other potentially nephrotoxic medicinal products.
Estonian: Ettevaatust nõuab zoledroonhappe kasutamine koos teiste potentsiaalselt nefrotoksiliste ravimitega.
English: † Identified in post-marketing experience.
Estonian: † Teatatud turuletulekujärgselt.
English: Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed.
Estonian: Patsiente, kes on saanud soovitatust suuremaid annuseid, tuleb hoolega jälgida (vt lõik 4.2), kuna on täheldatud neerukahjustust (sh neerupuudulikkust) ja seerumi elektrolüütide (sh kaltsiumi, fosfori ja magneesiumi) sisalduse muutusi.
English: Bone histology was evaluated in 7 patients with Paget's disease 6 months after treatment with 5 mg zoledronic acid.
Estonian: Luu histoloogiat hinnati 6 kuud pärast ravi seitsmel Pageti tõvega patsiendil, keda raviti 5 mg zoledroonhappega.
English: It is normal that old bone is removed and is replaced with new bone material.
Estonian: Tavaliselt vananenud luukude eemaldatakse ja see asendub pidevalt uuega.
English: Table 5: Proportion of complete responders by day in the combined TIH studies Day 4
Estonian: Tabel 5: Ravile täielikult reageerinute osakaal kombineeritud TIH uuringutes 4. päev
English: It is important for you to drink at least 2 glasses of fluid (such as water), within a few hours before receiving Zoledronic Acid Hospira, as directed by your healthcare provider.
Estonian: Väga oluline on juua vähemalt 2 klaasi vedelikku (näiteks vett) paari tunni jooksul enne Zoledronic Acid Hospira kasutamist, nii nagu on tervishoiutöötaja teid juhendanud.
English: Of the 153 zoledronic acid-treated patients and 115 risedronate-treated patients who entered an extended observation study, after a median duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re-treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%).
Estonian: Jätku-uuringus osalenud 153 zoledroonhappe ravi saanud ja 115 risedronaadiga ravitud patsiendist oli pärast keskmiselt 3,8 aastat kestnud jälgimisperioodi korduva ravi vajaduse tõttu (kliiniline hinnang) jätku-uuringu lõpetanud patsientide osakaal kõrgem risedronaadi korral (48 patsienti ehk 41,7%) kui zoledroonhappe korral (11 patsienti ehk 7,2%).
English: Intravenously administered zoledronic acid is eliminated by a triphasic process: rapid biphasic disappearance from the systemic circulation, with half-lives of t½α 0.24 and t½β 1.87 hours, followed by a long elimination phase with a terminal elimination half-life of t½γ 146 hours.
Estonian: Veenisiseselt manustatud zoledroonhape elimineerub kolmefaasiliselt: kiire kahefaasiline süsteemne puhastumine, poolväärtusajad t½ 0,24 tundi ja t½ 1,87 tundi, millele järgneb pikk eliminatsioonifaas poolväärtusajaga t½ 146 tundi.
English: Table 6: Proportion of complete responders by day in the combined TIH studies Day 4
Estonian: Tabel 6: Ravile täielikult reageerinute osakaal kombineeritud TIH uuringutes 4. päev
English: Within three days after zoledronic acid administration, an acute phase reaction has commonly been reported, with symptoms including bone pain, fever, fatigue, arthralgia, myalgia, rigors and arthritis with subsequent joint swelling; these symptoms usually resolve within a few days (see description of selected adverse reactions).
Estonian: Sageli on kolme päeva jooksul pärast zoledroonhappe manustamist teatatud ägeda faasi reaktsioonist, mille sümptomitena võivad esineda luuvalu, palavik, väsimus, artralgia, müalgia, külmavärinad ja artriit, millele järgneb liigeste turse; need sümptomid taanduvad tavaliselt mõne päeva jooksul (vt „Valitud kõrvaltoimete kirjeldus“).
English: It is currently unclear whether zoledronic acid causes this irregular heart rhythm but you should report it to your doctor if you experience such symptoms after you have received Zoledronic Acid Hospira.
Estonian: Siiani ei ole selge, kas zoledroonhape põhjustab ebaregulaarset südame löögisagedust, kuid te peate teatama oma arstile, kui teil tekivad pärast Zoledronic Acid Hospira manustamist sellised sümptomid.
English: In the trial for the prevention of clinical fractures following a recent hip fracture, vitamin D levels were not routinely measured but the majority of patients received a loading dose of vitamin D prior to zoledronic acid administration (see section 4.2).
Estonian: Hiljutisele reieluu proksimaalse osa murrule järgnevate kliiniliste murdude ennetamise uuringus ei määratud D-vitamiini taset rutiinselt, kuid enamik patsiente sai enne zoledroonhappe manustamist löökannuse D-vitamiini (vt lõik 4.2).
English: Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Estonian: Teatage oma arstile, apteekrile või meditsiiniõele, kui te kasutate või olete hiljuti kasutanud või kavatsete kasutada mis tahes muid ravimeid.
English: The following properties have been demonstrated in preclinical studies:
Estonian: Prekliinilistes uuringutes on täheldatud järgmisi omadusi:
English: Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily.
Estonian: Patsiendid peavad lisaks võtma suu kaudu 500 mg kaltsiumi ja 400 RÜ D-vitamiini ööpäevas.
English: Zoledronic Acid Hospira is not recommended for anyone under 18 years of age.
Estonian: Zoledronic Acid Hospira't ei soovitata alla 18-aastastele isikutele.
English: − Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid.
Estonian: - Katsetuste jooksul mitmete erinevat tüüpi polüvinüülkloriidist, polüetüleenist ja polüpropüleenist mahutitega ei esinenud kokkusobimatust zoledroonhappega.
English: Date of first authorisation: 19 November 2012 Date of latest renewal: 24 August 2017
Estonian: Müügiloa viimase uuendamise kuupäev: 24. august 2017
English: In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4).
Estonian: Kliinilistes uuringutes jätkati ravi zoledroonhappega alles siis, kui kreatiniini väärtus ei erinenud rohkem kui 10% algväärtusest (vt lõik 4.4).
English: - if you have had sections of your intestine removed.
Estonian: - kui teil on osa sooltest eemaldatud.
English: Follow carefully all instructions given to you by your doctor.
Estonian: Järgige täpselt kõiki arstilt saadud juhiseid.
English: The usual dose is 5 mg, given to you as one single infusion into a vein by your doctor or nurse.
Estonian: Tavaline annus on 5 mg, mille manustab arst või õde teile esialgse infusioonina veeni.
English: − Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection.
Estonian: - Pidage nõu oma arstiga, kui teil on kõrvavalu, eritis kõrvast ja/või kõrvapõletik.
English: − Conjunctivitis.
Estonian: - Konjunktiviit.
English: Furthermore, there is evidence of an association between hypocalcaemia and secondary neurological events reported in these cases including; convulsions, hypoaesthesia and tetany (see section 4.4).
Estonian: Lisaks esineb tõendatud seos hüpokaltseemia ning sekundaarsete neuroloogiliste juhtumite vahel, sh krambid, hüpoesteesia ja tetaania (vt lõik 4.4).
English: Risk reduction of suffering from multiple events** (%)
Estonian: Hulgitüsistuste riski vähenemine**
English: Acquired Fanconi syndrome General disorders and administration site conditions Common:
Estonian: Omandatud Fanconi sündroom Üldised häired ja manustamiskoha reaktsioonid Sage:
English: − Severe allergic reaction: shortness of breath, swelling mainly of the face and throat.
Estonian: - Raskekujuline allergiline reaktsioon: hingeldus, paistetus peamiselt näo ja kurgu piirkonnas.
English: Concentrate for solution for infusion (sterile concentrate)
Estonian: Infusioonilahuse kontsentraat (steriilne kontsentraat)
English: − Osteonecrosis has also very rarely been seen occurring with other bones than the jaw, especially the hip or thigh.
Estonian: - Osteonekroosi on täheldatud väga harva ka mujal kui lõualuus, eriti puusas või reies.
English: Due to the rapid onset of effect of zoledronic acid on bone turnover, transient hypocalcaemia, sometimes symptomatic, may develop and is usually maximal within the first 10 days after infusion of zoledronic acid (see section
Estonian: Kuna zoledroonhappe luukoe ainevahetust mõjutav toime algab kiiresti, võib esineda mööduvat, mõnikord sümptomaatilist hüpokaltseemiat, seda eriti esimese kümne päeva jooksul pärast zoledroonhappe infusiooni (vt lõik
English: Very Rare (may affect up to 1 in 10,000 people) Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection.
Estonian: Väga harv (võib esineda kuni ühel inimesel 10 000-st) Pidage nõu oma arstiga, kui teil on kõrvavalu, eritis kõrvast ja/või kõrvapõletik.
English: Although no teratogenicity or foetotoxicity was observed in the rabbit, maternal toxicity was found.
Estonian: Kuigi küülikutel ei täheldatud teratogeensust või lootetoksilisust, esines siiski toksiline toime emasloomale.
English: Before stopping Zoledronic Acid Hospira therapy If you are considering stopping Zoledronic Acid Hospira treatment, please go to your next appointment and discuss this with your doctor.
Estonian: Enne ravi lõpetamist Zoledronic Acid Hospira'ga Kui te kaalute ravi lõpetamist Zoledronic Acid Hospira'ga, siis palun minge oma järgmisele vastuvõtule ja arutage seda arstiga.
English: - Anti-angiogenic medicines (used to treat cancer), since the combination of these with Zoledronic Acid Hospira has been associated with an increased risk of osteonecrosis of the jaw (ONJ).
Estonian: - anti-angiogeenseid ravimeid (vähiravimid), kuna nende kombinatsiooni Zoledronic Acid Hospira'ga on seostatud lõualuu osteonekroosi (LON) tõusnud riskiga.
English: Zoledronic Acid Hospira recommended dose* 4.0 mg zoledronic acid 3.5 mg* zoledronic acid 3.3 mg* zoledronic acid 3.0 mg* zoledronic acid * Doses have been calculated assuming target AUC of 0.66 (mg•hr/l) (CLcr = 75 ml/min).
Estonian: Zoledronic Acid Hospira soovitatav annus* 4,0 mg zoledroonhapet 3,5 mg* zoledroonhapet 3,3 mg* zoledroonhapet 3,0 mg* zoledroonhapet *annused on arvestatud lähtuvalt soovitavast AUC väärtusest 0,66 (mg•h/l) (CLcr = 75 ml/min).
English: Zoledronic acid 4 mg (N=86)
Estonian: Zoledroonhape 4 mg (n=86)
English: 82.6% (p=0.005)* 88.4% (p=0.002)*
Estonian: 45,3% (p=0,104) 82,6% (p=0,005)* 88,4% (p=0,002)*
English: Your doctor, pharmacist or nurse knows how to store Zoledronic Acid Hospira properly.
Estonian: Teie arst, apteeker või meditsiiniõde teab, kuidas Zoledronic Acid Hospira't õigesti säilitada.
English: Patients were evenly distributed between zoledronic acid -treated and placebo groups.
Estonian: Patsiendid jagunesid zoledroonhappe ja platseeborühma vahel võrdselt.
English: There was a transient increase in serum creatinine observed within 10 days in 1.8% of zoledronic acid-treated patients versus 0.8% of placebo-treated patients.
Estonian: Mööduvat seerumi kreatiniini taseme tõusu esines 10 päeva jooksul 1,8%-l zoledroonhappega ravitud patsientidel versus 0,8%-l platseebot saanud patsientidel.
English: Follow carefully all instructions given to you by your doctor or nurse.
Estonian: Järgige hoolikalt kõiki teie arsti või õe poolt antud juhiseid.
English: Zoledronic Acid Hospira can be given to people aged 65 years and over.
Estonian: Zoledronic Acid Hospira't võivad kasutada ka 65-aastased ja vanemad patsiendid.
English: Healthcare professionals are advised not to dispose of unused Zoledronic Acid Hospira via the domestic sewage system.
Estonian: Tervishoiutöötajatel soovitatakse kasutamata Zoledronic Acid Hospira lahust mitte kallata kanalisatsioonisüsteemi.
English: Limited pharmacokinetic data in children with severe osteogenesis imperfecta suggest that zoledronic acid pharmacokinetics in children aged 3 to 17 years are similar to those in adults at a similar mg/kg dose level.
Estonian: Piiratud farmakokineetilised andmed, mis raskekujulise osteogenesis imperfecta'ga laste kohta olemas on, viitavad sellele, et 3…17-aastastel lastel on zoledroonhappe farmakokineetika sarnase mg/kg annuse korral samasugune nagu täiskasvanutel.
English: The majority of these reactions occur within the first three days following zoledronic acid administration.
Estonian: Enamik kõrvaltoimetest esines esimese kolme päeva jooksul peale zoledroonhappe manustamist.